CMS intends a significant drop in reimbursement for 340B drug payment program participants, along with potentially burdensome reporting requirements for non-participants. This article was originally ...
Hospitals and clinics told regulators that switching to rebates in the 340B drug discount program would impose costs that ...
The Centers for Medicare & Medicaid Services (“CMS”) has finalized and proposed several significant changes affecting both site neutrality in Medicare payments and the 340B Drug Pricing Program. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results